GRI intends to aid existing biotech companies and found new ones which will commercialize technologies it develops, particularly drugs and diagnostics, said David Millhorn, director of GRI. Additional future growth will come from NIH-funded projects, Air Force collaborations, state BRTT funds and private industry collaborators.